Suggested remit: To appraise the clinical and cost effectiveness of histamine dihydrochloride with interleukin-2 within its marketing authorisation for maintenance treatment of acute myeloid leukaemia.
Status In progress
Process STA 2018
ID number 1627

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
17 April 2020 - 18 May 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 January 2020 In progress, Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance